Crowdonomics
All companies
MARCo Health logo

MARCo Health

Operating

MARCo Health, Inc.

Healthcare · Hillsdale, NJ · Founded 2018

Accessible mental healthcare via compassionate robots

Post-money valuation ⓘ
$7.8M
As of Dec 2022 · from Reg CF Offering (2022) · pre-money + amount raised, not a traded price
Total raised
$224,230
Crowd $49K · Private $175K · 2 rounds since 2022
Latest share price
$5.00
Reg CF · Common Stock · Sep 2022 offering price

Financials

FY2020–FY2025 · from SEC filings · hover any figure for its source
$910
−$18K
2020
$993
−$14K
2021
$4K
−$72K
2022
$10K
−$143K
2023
$132K
$2K
2024
$79K
$9K
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020 reviewed
FY2021 reviewed
FY2022
FY2023 unaudited
FY2024 unaudited
FY2025 unaudited
Income statement
Revenue
$910
$993
$3,889
$10,107
$131,901
$79,402
Cost of goods sold
$677
$551
$2,313
$7,130
$16,305
$7,643
Gross margin
26%
45%
41%
29%
88%
90%
Net income
-$18,007
-$13,777
-$71,805
-$143,439
$2,277
$8,715
Taxes paid
$0
$66
$0
$1,234
$3,036
$970
Balance sheet
Cash
$1,214
$267
$108,548
$8,945
$27,418
$33,607
Accounts receivable
$0
$0
$7,937
$114,938
$0
$52,937
Total assets
$29,388
$23,598
$152,582
$159,240
$77,155
$1,113,345
Short-term debt
$0
$0
$7,937
$0
$0
$204
Long-term debt
$0
$0
$0
$0
$0
$0
Total liabilities
$0
$0
$7,937
$0
$0
$204
Other
Headcount
—
6
11
8
6
6

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$7.7M
pre-money
Reg CF · Common · Sep 2022

Blue bars are the pre-money valuation the company stated for a priced round.

Share price over rounds

$5.00$2.50$2.5362
Sep 2022Sep 2022
Round offering price or verified disclosed saleDisclosed sale, unverified or year-only

Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.

Cap table

Share counts as of May 1, 2026
ClassOutstandingVotes / shareShare of totalLast price
Common Stock1,545,0001100.0%$5.00Sep 2022

Principal holders% as the filing states it, May 1, 2026

  • Jacob Boyle1,105,500 Common Stock71.5%of company
  • Everyone else (not named in filings)28.5%

Sold to the crowd

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Raised $49.2K / $1.2MInvestors 27Post-money $7.8M

Team

6 people
Jacob BoyleFounder
CEO, CTO, President, and Director

Jacob is an advanced robotics engineer by trade and a mental health advocate by passion. He has over 7 years experience in engineering robots and medical devices, having started his career as the lead engineer of a startup developing amphibious robots for a US Navy contract, only to leave to repurpose his skills for what he believes is a higher cause. Having spent years caring for friends and family with mental illness, as well as struggling with his own mental health, he takes his work very personally, and believes in treating every customer and client like they are his only priority.

Dr. Nigam Samal
Acting CTO

More than 20 years of experience in Technology and Finance

Dr. Nithin Krishna
Chief Clinical Officer

A brilliant M&A Healthcare Specialist and Entrepreneur, M.D., and clinical researcher with 15+ years experience in psychiatry and neuroscience

Attiq Amjad
CMO & Director

Attiq is a seasoned business professional with over 15 years of marketing, finance, and general management experience in the medical device and consumer goods industries. Attiq holds an MBA in marketing from Seton Hall University and a B.S. in Finance from Rutgers University.

John Byrne
Healthcare & Business Valuation Specialist/ M&A Advisor/ CPA ABV

More than 25 years of experience in M&A Finance and Accounting

Tina Mulligan
Customer Success Manager

Accomplished professional counselor with a talent for providing social-emotional advising to adolescents, including at-risk youth and college-bound students.

Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFewer than 300 holders of record

Filed 4 of 4 annual reports (FY2022–FY2025)

27 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C-ARMay 1, 20260001948125-26-000002
    EDGAR
  • Form C-ARApr 9, 20250001665160-25-000550
    EDGAR
  • Form C-ARApr 9, 20240001665160-24-000331
    EDGAR
  • Form C-ARMar 31, 20230001665160-23-000512
    EDGAR
  • Form C-UJan 3, 20230001665160-23-000001
    EDGAR
  • Form CSep 30, 20220001665160-22-002570
    EDGAR
Source: ManualCIK 0001948125DEShare price $5.00

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.